Pharmaceuticals (Sep 2024)

Ischemic Optic Neuropathy: A Review of Current and Potential Future Pharmacotherapies

  • Omar Badla,
  • Beshr Abdulaziz Badla,
  • Amr Almobayed,
  • Carlos Mendoza,
  • Krishna Kishor,
  • Sanjoy K. Bhattacharya

DOI
https://doi.org/10.3390/ph17101281
Journal volume & issue
Vol. 17, no. 10
p. 1281

Abstract

Read online

The treatment of arteritic anterior ischemic optic neuropathy (AAION), non-arteritic ischemic optic neuropathy (NAAION), and posterior ischemic optic neuropathy (PION) is a topic of ongoing research with mixed evidence on some pharmacotherapies and a need for more consensus. This manuscript provides an overview of these conditions’ current, potential future, and attempted pharmacotherapies. AAION’s current treatment regimen consists of high-dose steroids, with methotrexate, tocilizumab, and abatacept, being the most viable steroid-sparing therapy candidates. As for NAAION, the treatments being tried are vast, with mixed evidence supporting each modality. Similarly, despite the various treatment options explored, there still needs to be a universally effective therapy for PION. More research is needed to formulate an agreed-upon treatment regimen for these conditions.

Keywords